Healthy volunteers
Conditions
Interventions
Subjects will receive one tablet of donepezil hydrochloride 10 mg
(Aricept® Evess) by oral route under fasting condition.,Subjects will receive one tablet of donepezil hydrochloride 10 mg
(NEPZIL&#
10) by oral route under fasting condition.
Active Comparator Drug,Active Comparator Drug
Aricept® Evess (Reference product),NEPZIL-
10 (Test product)
Sponsors
Pharmacy Service Center, Faculty of Pharmacy, Chiang Mai University
Pharmacy Service Center,
Faculty of Pharmacy,
Chiang Mai University
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1) Male and female subjects aged between 18-45 years 2) Body Mass Index (BMI) between 18.5-25.0 kg/m2 and body weight not less than 45 kg 3) Healthy subjects based on medical history and physical examination 4) Normal or not clinically significant abnormal of clinical laboratory results including blood urea nitrogen (BUN), serum creatinine (SCr), AST, ALT, total bilirubin, direct bilirubin, alkaline phosphatase, total protein, fasting blood glucose, complete blood count, and urinalysis 5) Clinical laboratory result of hepatitis B is negative. 6) No clinically significant findings in vital sign measurement 7) Nonsmoker or stop smoking for at least 6 months 8) Females who participate in this study are: 8.1) Nonpregnant female (negative result for pregnancy test) 8.2) With childbearing potential, whom must commit to using acceptable non-hormonal contraceptive method of birth control for at least 2 weeks before and during the study and 2 weeks after drug administration in period 2 as judged by the clinical investigators, such as condoms, non-hormonal intrauterine device (IUD), or willing to remain abstinence (not engage in sexual intercourse) 8.3) Not currently breastfeeding 9) Subjects are able, willing, and likely to comply with study procedures and restrictions.
Exclusion criteria
Exclusion criteria: 1) Subjects with a history of allergy to donepezil or related structure of donepezil or other components in the formulation 2) Subjects with currently or history of alcohol addiction or drug abuse 3) Subjects with currently or history of severe asthma, lung disease, seizures, gastrointestinal bleeding or ulcer, heart rhythm problem, hepatic, renal, endocrine, or cardiovascular diseases or any other conditions that may affect , bioavailability of the medication or safety of the subjects 4) Subjects who use of any aged including vitamins, herbal products, and dietary supplement, within 14 days before and during the study 5) Subjects who are unable to refrain from consumption of orange, pamelo, grapefruit within 7 days before and during the study 6) breastfeeding who are unable to refrain from caffeine-containing beverages and foods such as tea, coffee, cocoa, cola, chocolate or energy drink for 3 days before and during the study 7) Subjects with positive urine drug abuse test (methamphetamine, cannabinoid and opiates) 8) Subjects with positive alcohol breath test 9) Subjects with a history of blood donation greater than 300 ml or significant blood loss within 90 days before the initiation of the study 10) Subjects who participate in other clinical trials within 90 days before the initiation of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Donepezil concentration in plasma 0.0 - 72.0 h Cmax, AUC0-72h,Area Under the Plasma Concentration Time Curve From 0-72h 0.0 - 72.0 h LC-MS/MS | — |
Secondary
| Measure | Time frame |
|---|---|
| safety at the beginning and at the end of the trial. clinical and laboratory examinations | — |
Countries
Thailand
Contacts
Public ContactChuleegone Sornsuvit
Faculty of Pharmacy, Chiang Mai University
Outcome results
None listed